利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.022 秒)

    Process for producing an insulin
    1.
    发明授权
    Process for producing an insulin 失效
    胰岛素的制造方法

    公开(公告)号：US4421685A

    公开(公告)日：1983-12-20

    申请号：US262141

    申请日：1981-05-11

    申请人： Ronald E. Chance ,  James A. Hoffmann

    发明人： Ronald E. Chance ,  James A. Hoffmann

    IPC分类号： C07K1/06 ,  C07K1/12 ,  C07C103/52 ,  C07G7/00

    CPC分类号： C07K1/12 ,  C07K1/067

    摘要： Production of insulin or an insulin analog is provided by combination of an A-chain and a B-chain, which comprises bringing the S-sulfonated form of the A-chain, the S-sulfonated form of the B-chain, and a thiol reducing agent together in an aqueous medium under conditions which produce a mixture having (1) a pH of from about 8 to about 12, (2) a total protein concentration of from about 0.1 to about 50 milligrams per milliliter, and (3) an amount of thiol reducing agent which affords a total of from about 0.4 to about 2.5 --SH groups per each --SSO.sub.3.sup.- group present in the total amount of A- and B-chain S-sulfonates, and allowing formation of insulin or an insulin analog to occur by maintaining the mixture at a temperature of from about 0.degree. C. to about 25.degree. C. and in an environment which provides a source of oxygen.

    摘要翻译： 通过A链和B链的组合提供胰岛素或胰岛素类似物的生产，其包括使S-链的S-磺化形式，S-链的S-磺化形式和硫醇 （1）pH为约8至约12，（2）总蛋白质浓度为约0.1至约50毫克每毫升的混合物的条件下，在水性介质中一起在水性介质中，和（3） 量的硫醇还原剂，其存在于A-和B-链S-磺酸盐的总量中的每个-SSO 3 - 基团总共为约0.4至约2.5个-SH基团，并且允许形成胰岛素或胰岛素类似物 通过将混合物保持在约0℃至约25℃的温度和在提供氧源的环境中进行。

    Insulin formulation
    5.
    发明授权
    Insulin formulation 失效
    胰岛素制剂

    公开(公告)号：US5534488A

    公开(公告)日：1996-07-09

    申请号：US106106

    申请日：1993-08-13

    申请人： James A. Hoffmann

    发明人： James A. Hoffmann

    IPC分类号： A61K9/00 ,  A61K33/30 ,  A61K38/28 ,  A61K47/02 ,  A61P3/08 ,  A61P3/10 ,  C07K14/575 ,  C07K14/62

    CPC分类号： A61K47/02 ,  A61K38/28 ,  A61K9/0019

    摘要： The present invention is directed to an insulin formulation comprising a suspension of Ultralente crystals and a total formulation zinc concentration of between about 0.5 milligrams to about 20 milligrams per 100 units of insulin. Greater than fifty percent of the total zinc in the formulation resides in the soluble fraction, rather than in complex with the insulin. This insulin formulation generally has a pH from between about 6.0 to about 7.4. In addition, the insulin formulation of the present invention does not contain other proteins like protamine. This zinc-modified formulation displays characteristics of a very long lasting human insulin product.

    摘要翻译： 本发明涉及包含Ultralente晶体悬浮液和总配方锌浓度在约0.5毫克至约20毫克/ 100单位胰岛素之间的胰岛素制剂。 制剂中总锌的百分之五十以上是可溶性成分，而不是与胰岛素复合。 该胰岛素制剂通常具有约6.0至约7.4之间的pH。 此外，本发明的胰岛素制剂不含其他蛋白质，如鱼精蛋白。 该锌改性制剂显示出非常持久的人胰岛素产品的特征。